Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TONIC: Adaptive Phase II Trial of Nivolumab After Induction in Metastatic TNBC
2025-520487-18-00Phase 2Authorised
- Sponsor
- Netherlands Cancer Institute
- Start
- Jan 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nivolumab in triple-negative breast cancer (TNBC) (2 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Progression-free survival (PFS1) per RECIST 1.1. Planned start Jan 2025; status: authorised.
02
Drugs
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2025-520487-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520487-18-00.